New cancer drug GEN1106 enters first human tests
NCT ID NCT07416123
First seen Feb 18, 2026 · Last updated Apr 28, 2026 · Updated 9 times
Summary
This early-stage trial tests a new drug, GEN1106, in about 103 people with solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then, refining the dose; and finally, checking how well the drug shrinks tumors. All participants receive the active drug, and the trial lasts about 17 months per person, including treatment and follow-up.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Carolina Urologic Research Center
RECRUITINGMyrtle Beach, South Carolina, 29572, United States
-
START New York Long Island LLC
RECRUITINGLake Success, New York, 11042, United States
-
South Texas Accelerated Research Therapeutics
RECRUITINGSan Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.